The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Tonix Pharmaceuticals Announces Issuance of US Patent

02-May-2017 | Source : Tonix Pharmaceuticals Holding Corp | Visits : 4881
NEW YORK - Tonix Pharmaceuticals Holding Corp., a company that is developing innovative pharmaceutical products to address public health challenges, announced in a press release the issuance of US Patent No. 9,636,408 (‘408 patent) by the US Patent and Trademark Office. The patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” claims the composition and manufacture of a unique formulation that characterizes TNX-102 SL*. The ‘408 patent is expected to provide Tonix with US market exclusivity until 2034.

“The formulation of TNX-102 SL enables the transmucosal delivery of cyclobenzaprine that has been shown to be active in treating military-related posttraumatic stress disorder, or PTSD,” commented Seth Lederman, M.D., president and chief executive officer of Tonix. “The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the ‘408 patent are important elements of our proprietary TNX-102 SL composition.”

*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.

Tonix is developing innovative pharmaceutical products to address public health challenges. TNX-102 SL is in Phase 3 development for the treatment of PTSD and the HONOR study is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy of TNX-102 SL 5.6 mg in participants with military-related PTSD.  PTSD is a serious condition characterized by chronic disability, inadequate treatment options, especially for military-related PTSD, and an overall high utilization of healthcare services that contributes to significant economic burdens. Other development efforts include TNX-801, a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus and TNX-601 (tianeptine oxalate), a clinical candidate at the Pre-IND (Investigational New Drug) application stage.  It is designed for daytime use for the treatment of PTSD.

Related Articles